Rajesh Power Services wins multiple 11KV MVCC contracts from MGVCL
By Aman Shukla Published on June 4, 2025, 10:10 IST
Rajesh Power Services has been confirmed as the Lowest Bidder (L1) and successful bidder for multiple projects awarded by Madhya Gujarat Vij Company Limited (MGVCL). The contracts include turnkey work involving the supply, installation, testing, and commissioning of 11KV Medium Voltage Covered Conductor (MVCC) across various locations.
The awarded projects are as follows:
Supply, installation, testing, and commissioning of 11KV MVCC under the Kisan Suryoday Yojna (KSY) scheme at different locations managed by MGVCL.
Similar turnkey work for 11KV MVCC in the Bodeli and Dabhoi divisions under the VKY-2 scheme of MGVCL.
Supply and installation of 11KV MVCC in the Dahod and Lunawada divisions, also part of the VKY-2 scheme under MGVCL.
These contracts involve medium voltage electrical infrastructure work aimed at improving power distribution in the specified regions.
Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at BusinessUpturn.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
Why Recursion Pharmaceuticals (RXRX) Soared On Friday
We recently published a list of . In this article, we are going to take a look at where Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) stands against other Friday's best-performing stocks. Recursion Pharmaceuticals grew its share prices by 20.13 percent on Friday to close at $5.49 apiece following the unveiling of Boltz-2, touted as the next-generation AI model to predict binding affinity. According to Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), the new model is powered by its NVIDIA supercomputer for its training and validation, and represents the next step beyond existing biomolecular structure prediction models like AlphaFold3 and its predecessor, Boltz-1. A pharmacist in a hospital pharmacy stands next to a row of various drug containers. 'Selecting the right molecules early is one of the most fundamental challenges in drug discovery, with implications for whether R&D programs succeed or fail,' said Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Chief Commercial Officer Najat Khan. 'By predicting both molecular structure and binding affinity simultaneously with unprecedented speed and scale, Boltz-2 gives R&D teams a powerful tool to triage more effectively and focus resources on the most promising compounds. Collaborations like this, bridging academic innovation and industry application, play an important role in advancing the field and, ultimately, improving how we develop and deliver medicines for patients,' she added. Overall, RXRX ranks 2nd on our list of Friday's best-performing stocks. While we acknowledge the potential of RXRX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 hours ago
- Yahoo
Why Recursion Pharmaceuticals (RXRX) Soared On Friday
We recently published a list of . In this article, we are going to take a look at where Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) stands against other Friday's best-performing stocks. Recursion Pharmaceuticals grew its share prices by 20.13 percent on Friday to close at $5.49 apiece following the unveiling of Boltz-2, touted as the next-generation AI model to predict binding affinity. According to Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), the new model is powered by its NVIDIA supercomputer for its training and validation, and represents the next step beyond existing biomolecular structure prediction models like AlphaFold3 and its predecessor, Boltz-1. A pharmacist in a hospital pharmacy stands next to a row of various drug containers. 'Selecting the right molecules early is one of the most fundamental challenges in drug discovery, with implications for whether R&D programs succeed or fail,' said Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Chief Commercial Officer Najat Khan. 'By predicting both molecular structure and binding affinity simultaneously with unprecedented speed and scale, Boltz-2 gives R&D teams a powerful tool to triage more effectively and focus resources on the most promising compounds. Collaborations like this, bridging academic innovation and industry application, play an important role in advancing the field and, ultimately, improving how we develop and deliver medicines for patients,' she added. Overall, RXRX ranks 2nd on our list of Friday's best-performing stocks. While we acknowledge the potential of RXRX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 hours ago
- Yahoo
Ukrainian K-2 regiment's ground robots successfully evacuate four wounded soldiers in four days
The 20th K-2 Separate Unmanned Systems Regiment, led by Lieutenant Colonel Kyrylo Veres, has released a new video highlighting the use of ground-based robotic systems in rescuing soldiers. In the video, Veres says his regiment's robotic ground platforms have successfully evacuated four wounded soldiers in four days. Source: 20th K-2 Separate Unmanned Systems Regiment Quote: "Soon you will witness changes that will significantly increase the chances of survival for an ordinary infantryman. I'm not just talking about our unit, but about all the units in the defence forces. After all, K-2's job is to work in the interests of neighbouring brigades and save the lives of their men on the ground." Details: Veres added that following the successful use of drones in the air and at sea, the military is moving on to automate ground operations. One success story where a wounded soldier was evacuated with a ground drone was reported by the 13th Khartiia Brigade of the National Guard of Ukraine. The brigade successfully evacuated a wounded man using the Tarhan ("Cockroach") ground robotic system. The drone was able to deliver the wounded man to the evacuation team along a 12-km-long route. "The soldier in need of medical assistance was loaded onto the ground robotic system and successfully delivered to the evacuation team, from where he was taken to doctors," the team noted. This is further proof that the use of ground robotic systems is becoming increasingly common in the evacuation of wounded soldiers. More information about the use of ground drones in the Khartiia Brigade, including for the evacuation of military personnel, can be found in this article by Oboronka. Support Ukrainska Pravda on Patreon!
